Nevertheless, compared with single chemotherapy, PD-L1 inhibitor with chemotherapy for SCLC patients presented beneficial OS (A et al., 2019) (40), and there is increasing evidence that shows that combination therapy, such as combined with chemotherapy, radiotherapy, and other targeted therapy, may overcome the low response to ICI among SCLC patients (38, 41, 42). The gene discussed is CD274; the disease is small cell lung carcinoma.